HedgeChatter

  • Home /
  • Tag Archives

AMGN

Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases

[PR Newswire] – WHIPPANY, N.J., Feb. 20, 2014 /PRNewswire/ — Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga ® (regorafenib) tablets in colorectal cancer … moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, click here to […]

February 20, 2014 Bystocknews , Comments Off on Bayer Initiates Phase III Trial of Stivarga® (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases read more

Dako and Amgen Expand Collaboration with Plan to Develop New Diagnostic Test

[at noodls] – GLOSTRUP, Denmark, Feb. 11, 2014 Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced a new project with Amgen to develop a molecular diagnostic test using … moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, click here to view […]

February 19, 2014 Bystocknews , Comments Off on Dako and Amgen Expand Collaboration with Plan to Develop New Diagnostic Test read more

Amgen Increases Dividend 30%, But Is It A Buy?

moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, click here to view […]

February 17, 2014 Bystocknews , Comments Off on Amgen Increases Dividend 30%, But Is It A Buy? read more

PropThink: Biogen Idec’s BG-12 PDUFA Delay is a Buying Opportunity

[ACN Newswire] – By Ivan DeryuginThe biotechnology sector can be broken up, at its simplest, into two distinct groups: the Big 4, and every other company. The Big 4 are Amgen (NASDAQ:AMGN), Celgene (NASDAQ:CELG), Gilead … moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboard […]

October 31, 2012 Bystocknews , Comments Off on PropThink: Biogen Idec’s BG-12 PDUFA Delay is a Buying Opportunity read more